Fondo Health is an investment fund managed by Primo Capital SGR S.p.A. since January 8th, 2024.
The fund was launched in 2014 with the objective of investing in high-potential technology startups and SMEs in the healthcare sector. Its portfolio is composed of companies such as CrestOptics, European leader in the development and manufacturing of advanced systems for Fluorescence Microscopy, and CheckmAb, a biotech company focused on the development of novel monoclonal antibodies for cancer immunotherapy.
The fund is currently in its divestment phase. The investments underlying this financial product do not take into account the EU criteria for environmentally sustainable economic activities.
